The Epitalon discussion carried forward the central questions running throughout the past two days: what evidentiary standard applies under Section 503A, how much weight should be given to physician experience and real-world use, and whether FDA is evaluating the substance itself or the limitations of an incomplete nomination.
Epitalon added another layer to that debate. FDA evaluated it primarily for insomnia, while public commenters argued that the broader research and clinical interest relates to circadian regulation, melatonin production, biological markers associated with aging, and longevity.
Epitalon is a short synthetic peptide made up of four amino acids. It was developed through research involving epitalamin, a separate pineal-gland preparation studied outside the United States. Commenters described Epitalon as a “bioregulatory” peptide that may influence the body’s own melatonin production and has also been studied for its effects on telomerase and telomere length.
One supporter summarized the central concern as a “nomination quality problem, not a substance quality problem.”
FDA evaluated a narrow insomnia record
FDA explained that the nominations referenced several potential uses, including insomnia, circadian disorders, longevity, age-related disease, stress response, and cellular aging. The agency focused on insomnia because it found insufficient supporting information in the nomination to evaluate the other proposed uses.
FDA identified no study evaluating Epitalon in patients with insomnia or through the proposed subcutaneous route. It discussed one study involving 75 women in which Epitalon was administered sublingually for 20 days. Rather than measuring sleep outcomes, the study measured a urinary metabolite associated with melatonin production.
FDA acknowledged that the metabolite increased following treatment. During Committee questioning, FDA also confirmed that the study reported improvements in psycho-emotional and physical condition in approximately 83% of the Epitalon group, compared with 25% of the placebo group. FDA cautioned, however, that the publication did not adequately explain how those outcomes were measured.
The study therefore presented a clinical application, but it did not establish that Epitalon treats insomnia, and it involved a different route from the proposed injectable product.
Commenters argued that the prepared analysis did not reflect the larger record
Industry participants argued that FDA’s prepared analysis did not capture the broader Epitalon literature, particularly studies published in Russian and other foreign-language sources. Commenters stated that translated materials had been submitted addressing human exposure, melatonin regulation, circadian function, aging-related markers, and safety. FDA communicated that submitted characterization information had received only a preliminary review.
This repeated a process concern raised throughout the meeting: Committee members were required to vote after reviewing public submissions that FDA had not yet fully analyzed or incorporated into its presentation.
The distinction was particularly significant for Epitalon because, according to commenters, the nomination focused on insomnia while much of the available research addressed different biological and clinical questions.
The central safety question was telomerase and cancer
FDA’s principal theoretical safety concern involved Epitalon’s reported ability to increase telomerase activity and lengthen telomeres. Telomeres protect the ends of chromosomes and typically shorten as cells divide and age. Telomerase can preserve or restore that length. That mechanism may support cellular longevity, but telomerase activation is also associated with the ability of many cancer cells to continue dividing.
FDA therefore questioned whether prolonged or continuous Epitalon exposure could increase carcinogenic risk.
At the same time, the animal studies FDA reviewed did not demonstrate tumor promotion. Some reported fewer or smaller spontaneous tumors and increased lifespan. FDA’s concern was that those studies used limited doses and exposure patterns and did not establish what could occur with higher doses or continuous treatment over an entire lifespan.
Public commenters emphasized that Epitalon is typically used in short, intermittent courses—not through continuous exposure. One speaker described the cancer concern as presently “theoretical rather than demonstrated.” Others cited animal studies reporting tumor suppression rather than promotion.
The disagreement was not whether telomerase warrants scrutiny. It was whether a theoretical concern associated with higher or continuous exposure should outweigh the animal findings, reported human experience, and intermittent dosing patterns described during public comment.
FDA distinguished real-world data from real-world evidence
Several commenters presented retrospective pharmacy information. One speaker reported more than 14,000 source-identified Epitalon vials with only one complaint involving a cloudy vial—a product-quality observation rather than a reported clinical adverse event. Other commenters cited records involving more than 200,000 doses without a reported adverse event or immunogenicity reaction.
FDA cautioned that real-world data become meaningful evidence only when they are both relevant and reliable. The agency stated that retrospective reports may not consistently identify the patient population, indication, dose, duration, product source, method of follow-up, or whether adverse events were actively collected. FDA also reiterated that the absence of reported adverse events is not necessarily evidence that no risk exists.
Supporters argued that the retrospective information still reflected substantial reported exposure without an identified pattern of serious harm and should not be treated as though no human experience exists merely because it was not collected through a controlled clinical trial.
Quality testing again supported the argument for a regulated pathway
FDA found the nominations inconsistent as to whether Epitalon free base or Epitalon acetate had been nominated. The submitted certificates of analysis did not clearly align with the identified substances, and FDA alleged missing information involving impurities, aggregation, bioburden, bacterial endotoxins, solubility, and injectable-product quality.
Industry participants responded that Epitalon is a defined four-amino-acid peptide that can be identified and tested using established analytical methods, including mass spectrometry and high-performance liquid chromatography. They described controls for identity, potency, purity, residual solvents, elemental impurities, peptide-related impurities, TFA, endotoxins, sterility, particulate matter, and stability.
One domestic manufacturer also presented testing of Epitalon products obtained from the research-use-only market. According to the commenters presentation, every sample tested failed potency expectations, purity fell below 80% in some samples, and residual trifluoroacetic acid, or TFA, reached as high as 14 milligrams per gram. However, those findings did not establish that Epitalon itself is unsafe. They demonstrated the product-quality risks that can arise when products are supplied without consistent identity, purity, and release standards.
FDA responded that one manufacturer’s ability to produce a clean substance does not resolve the broader regulatory concern. Once a substance is placed on the Bulks List, FDA cannot limit it to a particular manufacturer, manufacturing method, or synthetic pathway.
As FDA explained: “They can make it however they want to make it once it’s on the list.”
That remained the core divide. Commenters argued that listing could create an incentive for qualified manufacturers and pharmacies to establish higher standards. FDA emphasized that it could not guarantee that every supplier would use those standards.
The Committee recommended inclusion
The Committee voted 7–4, with one abstention, to recommend adding Epitalon free base to the 503A Bulks List.
Members voting yes repeatedly emphasized that PCAC was applying the four-factor standard governing the 503A Bulks List—not the evidentiary standard for an Investigational New Drug application or FDA approval. One physician stated that the Committee appeared at times to be evaluating the peptides as though they were entering Phase 1 drug development, rather than determining whether a physician and pharmacist should be permitted to evaluate the risks and potential benefits for an individual patient.
Another affirmative voter stated that the applicable criteria had been met and emphasized that the Committee was not being asked to apply the burden of proof associated with FDA drug approval. Pharmacist members voting yes similarly focused on patient-specific prescriptions, professional oversight, and the distinction between individualized compounding and mass production for unidentified consumers. One affirmative voter also identified a mismatch between the real-world evidence submitted for Epitalon and the record reflected in FDA’s presentation.
Members voting no focused on physical and chemical characterization, the theoretical carcinogenicity concern associated with telomerase activation, and the lack of information needed to determine dose, frequency, and appropriate prescribing. One member described the record as containing a “significant lack of information and data to evaluate the product, and also how to prescribe it.” The National Association of Boards of Pharmacy representative abstained, maintaining the organization’s position neither supporting nor opposing peptide inclusion.
What the vote reflects
The affirmative recommendation was not a finding that Epitalon is FDA approved, proven effective for insomnia, or free from theoretical risk. It reflected a majority view that the applicable consideration criteria had been satisfied and that unresolved questions could be evaluated through patient-specific care involving a prescriber and pharmacist.
The opposing members viewed the same uncertainties differently. For them, the incomplete characterization, lack of established dosing, and unresolved implications of telomerase activation were too significant to support inclusion.
The 7–4 vote therefore reflected the central divide running throughout PCAC: whether incomplete evidence should prevent lawful access, or whether the 503A framework permits physicians and pharmacists to weigh uncertainty for an individual patient where no significant safety concern has been established.